No - if you believe that GSK are using best endeavours to market Relenza and IV Relenza
Yes - the royalty holders of both Tamiflu and Peramivir are both US companies - and you understand the history.
Mind you if IV Relenza popped up with a similar authorization then I would have no concerns - time will tell, but unlikely as the only trial was closed last year.
HTH
From a health and welbeing standpoint Perimavir will more than likely save many lives - a win win for all.
OR
BTA Price at posting:
$3.12 Sentiment: Hold Disclosure: Held
